Skin DiseasesNCT07359430
Deep Phenotyping of CIndU
An observational study of Skin Diseases and Angio-Oedema and/or Urticaria, run by Centre for Human Drug Research, Netherlands at 3 sites in Netherlands.
Trial summary
Chronic inducible urticaria (CIndU) is a group of skin disorders defined by recurrent itchy or burning wheals or angioedema that recur for more than six weeks with a specific triggering factor. This is different from chronic spontaneous urticaria which does not have a specific triggering factor. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Skin Diseases, Angio-Oedema and/or Urticaria
- How many people
- 40 participants
- Where
- 3 sitesNetherlands
- Study dates
- 21 Jan 2025to 1 Jun 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Healthy volunteers and patients
Who may be able to join
- Healthy volunteers
- Male and female subjects between 18-69 years of age; in general, stable good health as per judgement of the investigator based upon the results of a medical history, physical examination and vital signs.
- No clinically significant skin disease in the research area
- No history of hypertrophic scarring or keloid.
- Willing to give written informed consent and willing and able to comply with the study protocol.
- Negative TempTest and FricTest at screening.
Show all 18Show fewer
- Participant is willing to refrain from extensively washing (including bathing, swimming, showering and excessive sweating) the skin 12 hours before study visit 1.
- Eligible patients:
- Male and female subjects aged ≥18 years
- Diagnosis of SD, ColdU or CSU (moderate to severe according to international guidelines (Zuberbier et al, 2022)) for ≥3 months and symptomatic disease despite treatment with H1 antihistamines (up to fourfold the approved dose).
- Patients currently on an antihistamine (up to fourfold the approved dose) must be on a stable dose for at least 2 weeks prior to day 1 and must maintain the same stable dose throughout the treatment period. Patients are according to the stepped care model eligible to start treatment with omalizumab
- Willing to give written informed consent and willing and able to comply with the study protocol.
- Positive provocation test:
- For ColdU patients: developing a wheal at the test site within 10 min after using TempTest® at any temperature at both screening and Baseline. Alternatively, patients with a negative TempTest® may also be included if they have a positive ice cube test;
- For SD patients: developing a wheal at the test site within 10 min after using FricTest® with ≥ 3mm at both screening and Baseline.
- For CSU patients: negative TempTest® and FricTest® at screening
- Participant is willing to refrain from extensively washing (including bathing, swimming, showering and excessive sweating) the skin 12 hours prior to Day 1 and EOS.
- Female participants of reproductive potential must agree to use contraception from screening until EOS.
Who cannot join
- Significant, uncontrolled or unstable disease in any organ system as per judgment of the investigator (regardless of association with the immunosuppressing disorder/therapy), including but not limited to: psychiatric, neurologic, cardiovascular, pulmonary, gastrointestinal, hepatic, renal, endocrine, hematologic or respiratory disease.
- History of immunological abnormality (e.g., immune suppression) that may interfere with study objectives, in the opinion of the investigator.
- Loss or donation of blood over 500 mL within three months prior to screening.
- Positive hepatitis B surface antigen (HbsAg), hepatitis C antibody (HCV ab), or human immunodeficiency virus antibody (HIB ab) at screening
- Known infection requiring (topical or oral) antibiotic therapy within 56 days prior to Day 1.
- The use of systemic antibiotic therapy for >2 months the past 12 months.
Show all 27Show fewer
- The use of any oral/systemic medication (e.g. immunomodulatory, immunosuppressive) within 28 days prior to Day 1, if the investigator judges that it may interfere with the study objectives.
- Treatment with omalizumab within 5 half lives (120 days) prior to Day 1
- Pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding.
- Have any current and/or recurrent clinically significant or subject reported skin condition other than the CInDU/CSU wherefore subject is included in the study.
- Evidence of current drug or alcohol abuse.
- History of regular alcohol consumption within 12 months of the trial defined as an average weekly intake of >21 alcoholic drinks/week for men or >14 alcoholic drinks/week for women (i.e., 1 drink is equivalent to 150 mL of wine or 360 mL of beer or 45 mL of hard liquor)
- Healthy volunteers
- Participation in an investigational drug study within 3 months prior to screening or more than 4 times a year.
- Eligible patients
- For CIndU patients: active CSU or other forms of CIndU besides ColdU or SD that may interfere with study assessments. For CSU patients: presence of active CIndU disease that may interfere with study assessments.
- Urticarial or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema (eg, due to C1 inhibitor deficiency).
- Active, pruritic skin condition in addition to CIndU (CIndU patients) or CSU (CSU patients).
- Routine doses of the following medications within 30 days prior to Day 1: Systemic or cutaneous (topical) corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide.
- Intravenous (IV) immunoglobulin G (IVIG), or plasmapheresis within 30 days prior to screening.
- Regular (daily/every other day) doxepin (oral) use within 6 weeks prior to Day 1.
- Any H2 antihistamine use within 7 days prior to Day 1.
- Any leukotriene receptor antagonist (LTRA) (montelukast or zafirlukast) within 7 days prior to Day 1.
- Patients with current malignancy, history of malignancy, or currently under work-up for suspected malignancy except non-melanoma skin cancer that has been treated or excised and is considered resolved.
- Hypersensitivity to omalizumab or any component of the formulation.
- History of anaphylactic shock.
- Evidence of parasitic infection.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Netherlands3 sites, 2 recruiting
- Completed
Centre for Human Drug Research
Leiden, South Holland, 2333CL
- Recruiting
Erasmus Medical Center
Rotterdam, South Holland, 3015 GD
Fauve van den Berge, 010 704 0704, info@erasmusmc.nl
- Recruiting
University Medical Center Utrecht
Utrecht, Utrecht, 3584CX
Juliette Simons, 088 755 5555, info@umcutrecht.nl
About this study
Official title: An Exploratory, Multi-centre, Two-part Study to Describe Chronic Induced Urticaria Characteristics and Explore Novelbiomarkers With a Multimodal Patient Profiling Approach by Comparing CIndU Patients to Chronic Spontaneousurticaria Patients and Healthy Volunteers
Chronic inducible urticaria (CIndU) is a group of skin disorders defined by recurrent itchy or burning wheals or angioedema that recur for more than six weeks with a specific triggering factor. This is different from chronic spontaneous urticaria which does not have a specific triggering factor. CIndU is subclassified in nine subtypes with each having its own specific trigger. These subtypes are further divided in physical urticarias (symptomatic dermographism, cold urticaria, delayed pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema) or non-physical urticarias, i.e., cholinergic urticaria, aquagenic urticaria, and contact urticaria.
Symptomatic dermographism (SD) is the most prevalent subtype of the physical urticarias. Its prevalence in Western populations is estimated to be between 1-5%. Following SD, cold urticaria (ColdU) is the next most common form, its annual incidence is estimated to be 0.05%. In this study, patients with the ColdU and symptomatic SD subtypes will be enrolled.
As of yet, disease diagnosis of SD and ColdU is mostly purely clinical (clinical picture + patients' history), as there is a lack of objective biomarkers. Currently only two objective tools are available for the diagnosis of SD and ColdU, which are the FricTest and Temptest (both provocation tests). In addition, there is a lack of objective biomarkers for the prediction of treatment response and for the monitoring of treatment effects, as this is nowadays only monitored by patient reported outcomes.
Read the detailed description
The objective of this study is to deep phenotype CIndU (subtype SD and ColdU) and detect novel biomarkers for diagnosis andtreatment response as well as establish methodologies for (non-) invasive monitoring of treatment effects in chronic inducible urticaria.
For this purpose, a study with a multi-modal approach will be performed for in-depth characterization of SD and ColdU. The study willconsist of 2 parts: in part A the biology of disease will be investigated, and in part B the response of the biomarkers to real-world treatment with omalizumab will be monitored (part B). The former to characterize objectively measured disease characteristics and mechanisms underlying its development, the latter to monitor response of the disease and its characteristics to standard of care treatment once in four weeks. The study focusses on cellular, molecular, biophysical, imaging and microbiome analyses in comparisonwith chronic spontaneous urticaria (CSU) patients and matched healthy volunteers.
- Conditions
- Skin Diseases, Angio-Oedema and/or Urticaria
- Keywords
- Chronic inducible urticaria, Symptomatic dermographism
- Medical subject headings
- Skin Diseases, Chronic Inducible Urticaria, Familial dermographism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Omalizumab | In this treatment arm, a total of 30 patients-comprising 10 with chronic spontaneous urticaria (CSU), 10 with symptomatic dermographism (SD), and 10 with cold urticaria (ColdU)-will receive omalizumab at a dose of 300 mg every 4 weeks. | |
| Healthy volunteers | As a control group, 10 healthy volunteers without a history of inflammatory skin disease or atopic conditions will be included. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Absolute eosiniphil count
cells/µL
Measured: Baseline - day 99
IgG-anti-FcεRI
IU/mL
Measured: Baseline - day 99
Absolute basophil count
cells/µL
Measured: Baseline - day 99
C-reactive protein
mg/L
Measured: baseline - day 99
D-dimer
µg/mL
Measured: Baseline - day 99
Complement assessment
mg/dL
Measured: Baseline - day 99
Total serum IgE
IU/mL
Measured: Baseline - day 99
Basophil activcation test (BAT)
% activation or Stimulation index
Measured: Baseline - day 99
Cytokine profile assessment
pg/mL
Measured: Baseline - day 99
Tissue mass cytometry (CyTOF)
Skin punch biopsies (4mm) will be taken from (non-)lesional skin and healthy for tissue mass cytometry (CyTOF).
Measured: Baseline - day 99
RNA-sequencing analysis
Skin punch biopsies (4mm) will be taken from (non-)lesional skin and healthy for RNA-sequencing analysis
Measured: Baseline - day 99
Next-generation sequencing of skin swabs
The microbiome is collected by swabbing. The abundance of bacteria is thereafter determined using next-generation sequencing.
Measured: Baseline - day 99
Composition and diversity of faecal microbiota
Faecal samples will be collected to measure the composition and diversity of gut microbiota.
Measured: Baseline - day 99
3D Multispectral imaging
The redness and superficial morphology of (non-)lesional skin sites and healthy skin will be determined using a 3D multispectral imaging system.
Measured: Baseline - day 99
Laser Speckle Contrast Imaging (LSCI)
The cutaneous microcirculation of (non-)lesional skin sites and healthy skin will be monitored over a 40 second timespan with a laser speckle contrast imager.
Measured: Baseline - day 99
2D photography
Standardized 2D clinical photographs will be taken of lesional and non-lesional skin, as well as healthy control skin, to build a longitudinal photo library for visual assessment of disease morphology and treatment response over time.
Measured: Baseline - day 99
Secondary outcomes (9)
Urticaria Activity Score over 7 days (UAS7)
The Urticaria Activity Score over 7 days (UAS7) is a validated patient-reported outcome measure used to assess the severity and frequency of urticaria symptoms-specifically wheals (hives) and pruritus (itch)-over the previous week. Scores range from 0 to 42, with higher scores reflecting more severe disease activity. The UAS7 is applied exclusively in patients with chronic spontaneous urticaria (CSU) to monitor disease burden and evaluate treatment response.
Measured: Baseline - day 99
Urticaria Control Test (UCT)
The Urticaria Control Test (UCT) is a validated patient-reported outcome measure used to assess disease control in patients with chronic spontaneous urticaria (CSU). The total UCT score ranges from 0 to 16, with higher scores indicating better disease control. This questionnaire is used exclusively in patients with CSU to monitor treatment response and disease management over time.
Measured: Baseline - day 99
Dermatology Life Quality Index (DLQI)
The Dermatology Life Quality Index (DLQI) is a validated patient-reported outcome measure that assesses the impact of skin diseases on patients' quality of life over the previous week. The total DLQI score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. A score of 0 reflects no impact, whereas 30 represents the most severe impact on quality of life. The DLQI will be assessed in all patients across the included skin disease cohorts.
Measured: Baseline - day 99
Symptomatic Dermographism Activity Score (SDAS)
The Symptomatic Dermographism Activity Score (SDAS) is a patient-reported outcome measure specifically designed to assess disease activity in individuals with symptomatic dermographism. Patients rate the severity of their symptoms, such as itching and whealing, over the previous 24 hours on a scale from 0 to 4, with higher scores indicating more severe symptoms. The SDAS will be assessed daily in patients with symptomatic dermographism throughout the study to monitor disease activity and treatment response.
Measured: Baseline - day 99
Symptomatic Dermographism Quality of Life Questionnaire (SD-QoL)
The Symptomatic Dermographism Quality of Life Questionnaire (SD-QoL) is a disease-specific, patient-reported outcome measure that evaluates the impact of symptomatic dermographism on patients' daily functioning and well-being. It covers domains such as symptoms, emotional burden, and social limitations, with higher scores indicating greater impairment in quality of life. The SD-QoL will be administered to all patients with symptomatic dermographism to assess the condition's impact over time and in response to treatment.
Measured: Baseline - day 99
Cold Urticaria Activity Score (ColdUAS)
The Cold Urticaria Activity Score (ColdUAS) is a patient-reported outcome measure used to assess daily disease activity in individuals with cold urticaria. Patients rate the severity of their symptoms, such as itching, whealing, and swelling, over the previous 24 hours on a scale from 0 to 3 for each symptom, with higher scores reflecting greater disease activity. The ColdUAS will be completed daily by patients with cold urticaria throughout the study to monitor fluctuations in disease activity and evaluate treatment effects.
Measured: Baseline - day 99
Cold Urticaria Quality of Life Questionnaire (ColdU-QoL)
The Cold Urticaria Quality of Life Questionnaire (ColdU-QoL) is a disease-specific, patient-reported outcome measure that assesses the impact of cold urticaria on various aspects of daily life, including symptoms, emotional well-being, and social and occupational functioning. Higher scores indicate greater impairment in quality of life. The ColdU-QoL will be administered to all patients with cold urticaria to evaluate the burden of disease and changes in quality of life over the course of treatment.
Measured: Baseline - day 99
Activity Tracking Sleep
Subjects are requested to wear a smartwatch at all times which register sleep (hrs, minutes, seconds of rest)
Measured: Baseline - day 99
Activity Tracking Steps
Subjects are requested to wear a smartwatch at all times which register steps (amount of steps taken)
Measured: Baseline - day 99
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2026
- Study start21 Jan 2025
- Primary completion1 Jun 2026 (estimated)
- Study completion1 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre for Human Drug Research, Netherlands
- Sponsor type
- University, hospital or other
- Collaborators
- UMC Utrecht, Erasmus Medical Center
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07359430
- Sponsor's protocol ID
- CHDR2324
- Status last verified
- Jan 2026
- First submitted
- 11 Jun 2025
- Last updated
- 22 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Exploratory, Multi-centre, Two-part Study to Describe Chronic Induced Urticaria Characteristics and Explore Novelbiomarkers With a Multimodal Patient Profiling Approach by Comparing CIndU Patients to Chronic Spontaneousurticaria Patients and Healthy Volunteers
- ClinicalTrials.gov ID
- NCT07359430
- Acronym / sponsor ID
- CHDR2324
- Conditions
- Skin Diseases, Angio-Oedema and/or Urticaria
- Keywords
- Chronic inducible urticaria, Symptomatic dermographism
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Centre for Human Drug Research, NetherlandsUniversity, hospital or other
- Collaborators
- UMC Utrecht, Erasmus Medical Center
- Study start
- 21 Jan 2025 (actual)
- Primary completion
- 1 Jun 2026 (estimated)
- Study completion
- 1 Jun 2026 (estimated)
- First posted
- 22 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic inducible urticaria (CIndU) is a group of skin disorders defined by recurrent itchy or burning wheals or angioedema that recur for more than six weeks with a specific triggering factor. This is different from chronic spontaneous urticaria which does not have a specific triggering factor. CIndU is subclassified in nine subtypes with each having its own specific trigger. These subtypes are further divided in physical urticarias (symptomatic dermographism, cold urticaria, delayed pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema) or non-physical urticarias, i.e., cholinergic urticaria, aquagenic urticaria, and contact urticaria.
Symptomatic dermographism (SD) is the most prevalent subtype of the physical urticarias. Its prevalence in Western populations is estimated to be between 1-5%. Following SD, cold urticaria (ColdU) is the next most common form, its annual incidence is estimated to be 0.05%. In this study, patients with the ColdU and symptomatic SD subtypes will be enrolled.
As of yet, disease diagnosis of SD and ColdU is mostly purely clinical (clinical picture + patients' history), as there is a lack of objective biomarkers. Currently only two objective tools are available for the diagnosis of SD and ColdU, which are the FricTest and Temptest (both provocation tests). In addition, there is a lack of objective biomarkers for the prediction of treatment response and for the monitoring of treatment effects, as this is nowadays only monitored by patient reported outcomes.
Detailed description
The objective of this study is to deep phenotype CIndU (subtype SD and ColdU) and detect novel biomarkers for diagnosis andtreatment response as well as establish methodologies for (non-) invasive monitoring of treatment effects in chronic inducible urticaria.
For this purpose, a study with a multi-modal approach will be performed for in-depth characterization of SD and ColdU. The study willconsist of 2 parts: in part A the biology of disease will be investigated, and in part B the response of the biomarkers to real-world treatment with omalizumab will be monitored (part B). The former to characterize objectively measured disease characteristics and mechanisms underlying its development, the latter to monitor response of the disease and its characteristics to standard of care treatment once in four weeks. The study focusses on cellular, molecular, biophysical, imaging and microbiome analyses in comparisonwith chronic spontaneous urticaria (CSU) patients and matched healthy volunteers.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Omalizumab | – | –In this treatment arm, a total of 30 patients-comprising 10 with chronic spontaneous urticaria (CSU), 10 with symptomatic dermographism (SD), and 10 with cold urticaria (ColdU)-will receive omalizumab at a dose of 300 mg every 4 weeks. |
| Healthy volunteers | – | –As a control group, 10 healthy volunteers without a history of inflammatory skin disease or atopic conditions will be included. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Healthy volunteers and patients
Key inclusion criteria (18 listed)
- Healthy volunteers
- Male and female subjects between 18-69 years of age; in general, stable good health as per judgement of the investigator based upon the results of a medical history, physical examination and vital signs.
- No clinically significant skin disease in the research area
- No history of hypertrophic scarring or keloid.
- Willing to give written informed consent and willing and able to comply with the study protocol.
Key exclusion criteria (27 listed)
- Significant, uncontrolled or unstable disease in any organ system as per judgment of the investigator (regardless of association with the immunosuppressing disorder/therapy), including but not limited to: psychiatric, neurologic, cardiovascular, pulmonary, gastrointestinal, hepatic, renal, endocrine, hematologic or respiratory disease.
- History of immunological abnormality (e.g., immune suppression) that may interfere with study objectives, in the opinion of the investigator.
- Loss or donation of blood over 500 mL within three months prior to screening.
- Positive hepatitis B surface antigen (HbsAg), hepatitis C antibody (HCV ab), or human immunodeficiency virus antibody (HIB ab) at screening
- Known infection requiring (topical or oral) antibiotic therapy within 56 days prior to Day 1.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Absolute eosiniphil count
Time frame: Baseline - day 99
cells/µL
IgG-anti-FcεRI
Time frame: Baseline - day 99
IU/mL
Absolute basophil count
Time frame: Baseline - day 99
cells/µL
C-reactive protein
Time frame: baseline - day 99
mg/L
D-dimer
Time frame: Baseline - day 99
µg/mL
Complement assessment
Time frame: Baseline - day 99
mg/dL
Total serum IgE
Time frame: Baseline - day 99
IU/mL
Basophil activcation test (BAT)
Time frame: Baseline - day 99
% activation or Stimulation index
Cytokine profile assessment
Time frame: Baseline - day 99
pg/mL
Tissue mass cytometry (CyTOF)
Time frame: Baseline - day 99
Skin punch biopsies (4mm) will be taken from (non-)lesional skin and healthy for tissue mass cytometry (CyTOF).
RNA-sequencing analysis
Time frame: Baseline - day 99
Skin punch biopsies (4mm) will be taken from (non-)lesional skin and healthy for RNA-sequencing analysis
Next-generation sequencing of skin swabs
Time frame: Baseline - day 99
The microbiome is collected by swabbing. The abundance of bacteria is thereafter determined using next-generation sequencing.
Composition and diversity of faecal microbiota
Time frame: Baseline - day 99
Faecal samples will be collected to measure the composition and diversity of gut microbiota.
3D Multispectral imaging
Time frame: Baseline - day 99
The redness and superficial morphology of (non-)lesional skin sites and healthy skin will be determined using a 3D multispectral imaging system.
Laser Speckle Contrast Imaging (LSCI)
Time frame: Baseline - day 99
The cutaneous microcirculation of (non-)lesional skin sites and healthy skin will be monitored over a 40 second timespan with a laser speckle contrast imager.
2D photography
Time frame: Baseline - day 99
Standardized 2D clinical photographs will be taken of lesional and non-lesional skin, as well as healthy control skin, to build a longitudinal photo library for visual assessment of disease morphology and treatment response over time.
9 secondary outcomes
Urticaria Activity Score over 7 days (UAS7)
Time frame: Baseline - day 99
Urticaria Control Test (UCT)
Time frame: Baseline - day 99
Dermatology Life Quality Index (DLQI)
Time frame: Baseline - day 99
Symptomatic Dermographism Activity Score (SDAS)
Time frame: Baseline - day 99
Symptomatic Dermographism Quality of Life Questionnaire (SD-QoL)
Time frame: Baseline - day 99
Cold Urticaria Activity Score (ColdUAS)
Time frame: Baseline - day 99
Cold Urticaria Quality of Life Questionnaire (ColdU-QoL)
Time frame: Baseline - day 99
Activity Tracking Sleep
Time frame: Baseline - day 99
Activity Tracking Steps
Time frame: Baseline - day 99
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Skin Diseases
Recruiting
Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)
Systemic Sclerosis (SSc)
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingObservational study
Study of Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
RecruitingPhase 2
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Adjustment Disorder, Adjustment Disorder With Anxious Mood
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Skin Diseases and Angio-Oedema and/or Urticaria, run by Centre for Human Drug Research, Netherlands at 3 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Absolute eosiniphil count (time frame: Baseline - day 99). The study lists 16 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2026.